Studies On Identification Synthesis Of Several Process Degradation And Nsa Impurities Of Functional Active Pharmaceutical Ingredients Api s

Abstract

Any substance or combination of substances used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings1.quot newline newline1.2. Impurities2: Impurities in new drug substances (API s) are addressed from two perspectives: newline1.2.1. Chemistry Aspects include classification and identification of impurities, report generation, listing of impurities in specifications, and a brief discussion of analytical procedures newline1.2.2. Safety Aspects include specific guidance for qualifying those impurities that were not present, or were present at substantially lower levels, in batches of a new drug substance used in safety and clinical studies. newline newlineFurther, these impurities can be classified into the following categories: newline1.2.3. Organic impurities (process- and drug-related): Organic impurities can arise during the manufacturing process and/or storage of the new drug substance. They can be identified or unidentified, volatile or non-volatile, and including Starting materials, By- products, Intermediates, Degradation products, Reagents. Etc. newline1.2.4. Inorganic impurities: Reagents, ligands and catalysts, Heavy metals or other residual metals, Inorganic salts, other materials (e.g., filter aids, charcoal). newline1.2.5. Residual solvents: Solvents are inorganic or organic liquids used as vehicles for the preparation of solutions or suspensions in the synthesis of a new drug substance. newline1.2.6. Mutagenic impurities3: degradation products, process related reagents, intermediates. Etc. designated upon their structural alerts. newline newline1.3. Nitroso Amine impurities 4: Nitrosamines are chemical compounds classified as probable human carcinogens on the basis of animal studies. The European Medicines Agency (EMA) has assessed the risk of nitrosamine formation or presence during the manufacture of human medicines and has provided guidance